Moderna (MRNA) vs BeOne Medicines (ONC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Moderna (MRNA) has outperformed BeOne Medicines (ONC) over the past year, gaining 618.7% versus a gain of 6.6%. Over five years, ONC leads with a +1.6% price change compared with -39.4% for MRNA. Moderna is the larger company by market cap ($78.77 billion vs $38.92 billion), about 2.0 times the size, while BeOne Medicines is growing revenue faster (+40.2% vs -39.9%).
BeOne Medicines converts more of its revenue into profit, with a net margin of 5.4% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRNA | ONC |
|---|---|---|
| Share price | $197.30 | $342.07 |
| Market cap | $78.77B | $38.92B |
| 1-day change | +0.42% | -6.03% |
| YTD return | +566.26% | +19.82% |
| 1-year return | +618.65% | +6.56% |
| 5-year return | -39.40% | +1.56% |
| P/E ratio (TTM) | — | 61.19 |
| Forward P/E | — | 33.37 |
| EPS (TTM) | $-7.98 | $5.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.94B | $5.34B |
| Revenue growth (YoY) | -39.93% | +40.23% |
| Net income (latest FY) | $-2.82B | $286.93M |
| Gross margin | 55.35% | 87.49% |
| Operating margin | -158.13% | 8.37% |
| Net margin | -145.16% | 5.37% |
| 52-week high | $212.22 | $385.22 |
| 52-week low | $22.28 | $253.95 |
| Distance from 52-week high | -7.03% | -11.20% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -38.67% | +27.23% |
| Average volume | 17.44M | 388.88K |
| Shares outstanding | 399.24M | 104.92M |
| Employees | 4,700 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 2.0 times larger than BeOne Medicines by market value ($78.77B vs $38.92B).
- MRNA has outperformed ONC by 612.1 percentage points over the past year.
- BeOne Medicines is more profitable, keeping 5.4 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs -39.93%).
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
MRNA vs ONC FAQ
Which is bigger, Moderna or BeOne Medicines?
Moderna (MRNA) is larger, with a market capitalization of $78.77B compared with $38.92B for BeOne Medicines (ONC).
Which stock has performed better over the past year, MRNA or ONC?
MRNA returned +618.65% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Are Moderna and BeOne Medicines in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Moderna and Biotechnology: Pharmaceutical Preparations for BeOne Medicines.